The top 20 trades made by SMSFs in August 2020
Disclaimer: This article is for informational purposes only and does not constitute a product recommendation, or taxation or financial advice and should not be relied upon as such. Please consult with your financial adviser or accountant to obtain the correct advice for your situation.
(This article was originally published on the Switzer Daily website)
The past 6 months have seen mass movement in the share market, with investors grappling with how to best organise their portfolios in the midst of a sudden global economic downturn. This includes self-managed super fund (SMSF) trustees, some of whom have needed to quickly re-evaluate their investment strategy to stem losses from plummeting share markets.
Each month, Sharesight highlights the top 20 stocks traded by its users in a range of global markets, and the market-moving news behind them. This article details the top 20 buy and sell trades made by SMSFs in August 2020. To find out the news behind these stocks, keep reading.
Many investors use Sharesight’s portfolio tracker to track the assets in their SMSF, as it allows them to track the performance of investments in global markets and a range of asset classes. As can be seen in the chart above, the month of August saw wide-ranging investments by SMSFs, with Mesoblast (ASX: MSB) and Commonwealth Bank (ASX: CBA) leading in both buy and sell trades, while investors also favoured Resmed (ASX: RMD), Afterpay (ASX: APT) and CSL (ASX: CSL). Here is the news behind some of August’s most interesting stocks:
Mesoblast (ASX: MSB) is a growing Australian biotech company that has seen surging share prices and a 90% increase in its revenue over the past year. The next few months will be critical for Mesoblast; the company is seeking FDA approval for its stem cell treatment, and is planning to launch a drug to treat Covid-19 complications by the end of 2020.
Commonwealth Bank (ASX: CBA) has always been a popular dividend stock for investors, although it has more recently become synonymous with scandal, being fined $700 million over money laundering allegations in 2018. Things may be looking up for CommBank; ASIC has dropped its follow-up investigation into the scandal, and the bank produced a higher-than-expected dividend despite falling profits due to Covid-19.
Afterpay (ASX: APT) has taken the investment world by storm with its rapid expansion and skyrocketing share prices. In the past month, the BNPL giant announced an $80 million European expansion deal, not to mention doubling its expected earnings for FY20. On the back of this news, Afterpay’s share price hit an all-time high at the end of August, bringing the company’s market cap up to $25.9 billion.
CSL (ASX: CSL) has seen strong growth in its share price over the past few years, becoming a portfolio staple for many Australian investors. The biotech company continues to see success, posting strong FY20 results and increasing its dividend payout, while also being the most likely candidate to manufacture Australia’s Covid-19 vaccine. The company has flagged a soft FY21, however.
Apple (NASDAQ: AAPL) has long been an investor favourite due to skyrocketing share prices that really took off after the first iPhone was released in 2007. The tech giant has continued to flourish throughout the pandemic, gaining $1 trillion in value since the NASDAQ bottomed out on March 23 this year. Apple has since become the first US company to hit a $2 trillion market cap, and saw its stock price rise to an all-time high before a 4-for-1 stock split on August 31.
Fortescue Metals (ASX: FMG) is currently one of the world’s biggest iron ore producers, and has seen exponential growth in its share price since 2019. Fortescue has continued to see success throughout the pandemic, with strong iron ore prices and production pushing the company’s FY20 net profit 49% higher to $6.6 billion. As a result, the miner increased its dividend, with company founder Andrew Forrest receiving $1.11 billion in final dividends.
Resmed (ASX: RMD) has been on analysts’ radars for a while, with its stock price climbing significantly over the past few years. The medical equipment company has been in a good position throughout Covid-19, with investors favouring its stock due to the company’s role in supplying ventilators and other crucial medical supplies. Despite posting strong results for Q4 2020, Resmed’s stock price declined, with some investors concerned about declining demand for the company’s sleep devices, as well as an expected decrease in ventilator sales as the pandemic subsides.
Zip Co (ASX: Z1P) is another BNPL startup that has seen massive growth recently, and is currently in a race with main competitor Afterpay to achieve global adoption of its technology. While the company reported a 61% increase in net bad debts and losses of $44.9 million in its preliminary FY20 results, much of this can be attributed to its expansion efforts. Zip also announced a partnership with eBay in August, and made moves to acquire leading US BNPL company Quadpay.
Join over 150,000 investors tracking their investment performance (and tax) with Sharesight.
Built for the needs of SMSF trustees, with Sharesight you can:
- Organise holdings according to your documented SMSF asset allocation and investment strategy, providing valuable insights throughout the year
- Easily share SMSF portfolios with accountants or financial professionals to make admin and tax compliance a breeze
- Track SMSF investment performance with prices, dividends and currency fluctuations updated automatically
- Run powerful tax reports built for Australian investors, including capital gains tax, unrealised capital gains, and taxable income (dividend income)
Sign up for a free Sharesight account and get started tracking your SMSF investments today.
How InstructAnt improves client service with Sharesight and AdviserLogic
We talk to InstructAnt, a small accounting and financial planning firm that uses the Sharesight/AdviserLogic integration to improve client service.
Australian ETF distribution components now available for FY22/23
Sharesight now has updated ETF distribution component information for the FY22/23 Australian tax year for most Australian ETFs.
Sharesight product updates – September 2023
Major updates for the past month include the rollout of our new exposure report, plus support for five new brokers and over 80,000 Luxembourg funds.